Sugi Predict

Sugi Predict / Compounds / SCHEMBL2995308

SCHEMBL2995308

SCHEMBL2995308

CCOC(=O)C(CCCBr)C(=O)OCC

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 5/20 0.50
▸ MEN1 O00255 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ L3MBTL1 Q9Y468 6/20 0.44
▸ ALDH1A1 P00352 4/20 0.44
▸ MAPK1 P28482 4/20 0.44
▸ TSHR P16473 2/20 0.44
▸ TRPA1 O75762 1/20 0.43
▸ MAPT P10636 2/20 0.42
▸ CRHBP P24387 1/20 0.42
▸ CRHR2 Q13324 1/20 0.42
▸ POLB P06746 1/20 0.40
▸ PTPN1 P18031 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ LMNA P02545 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ CPB2 Q96IY4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15727419 0.94 TDP1 (0.49) TDP1MEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL9695685 0.92 TDP1 (0.47) TDP1MEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL4089564 0.92 TDP1 (0.47) TDP1MEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL10792134 0.92 TDP1 (0.47) TDP1MEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL9697656 0.92 TDP1 (0.47) TDP1MEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL550000 0.92 TDP1 (0.47) TDP1MEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL27873067 0.92 TDP1 (0.47) TDP1MEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL1703436 0.92 TDP1 (0.47) TDP1MEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL1702872 0.92 TDP1 (0.47) TDP1MEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL9328294 0.92 TDP1 (0.47) TDP1MEN1KMT2AL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2740738-B1 PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASE, PREPARATION METHODS AND USES THEREOF BEIJING FSWELCOME TECH DEVELOPMENT CO LTD (CN) 2018-03-28 — — EP disclosed
US-9138421-B2 Platinum compounds for treating cell proliferative diseases, preparation method and use thereof BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2015-09-22 — — US disclosed
US-9138421-B2 Platinum compounds for treating cell proliferative diseases, preparation method and use thereof BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2015-09-22 — — US disclosed
CN-102272170-B Solid catalyst component for olefin polymerization, manufacturing method, and catalyst and olefin polymer manufacturing method TOHO TITANIUM CO LTD 2014-06-18 — — CN disclosed
EP-2740738-A1 PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASE, PREPARATION METHODS AND USES THEREOF Beijing FSwelcome Technology Development Co., Ltd. (CN) 2014-06-11 — — EP disclosed
US-20140142079-A1 PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASES, PREPARATION METHOD AND USE THEREOF BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2014-05-22 — — US disclosed
US-20140142079-A1 PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASES, PREPARATION METHOD AND USE THEREOF BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2014-05-22 — — US disclosed
CN-103764690-A Process for producing solid catalyst component for olefin polymerization, catalyst for olefin polymerization, and process for producing olefin polymer TOHO TITANIUM CO LTD 2014-04-30 — — CN disclosed
CN-102643188-B Method for preparing 5-bromovalerate YUEYANG YETOP FINE CHEMICAL CO LTD 2014-04-16 — — CN disclosed
WO-2013007172-A1 PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASE, PREPARATION METHODS AND USES THEREOF 北京市丰硕维康技术开发有限责任公司 (CN) 2013-01-17 — — WO disclosed
CN-102272170-A Solid catalyst component for olefin polymerization, manufacturing method, and catalyst and olefin polymer manufacturing method — 2011-12-07 — — CN disclosed
US-7781470-B2 Aminodicarboxylic acid derivatives having pharmaceutical properties BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-08-24 — — US disclosed
US-20090203906-A1 NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES BAYER AKTIENGESELLSCHAFT (DE) 2009-08-13 — — US disclosed
US-7087644-B1 Derivatives of dicarboxylic acid having pharmaceutical properties BAYER AKTIENGESELLSCHAFT (DE) 2006-08-08 — — US disclosed
US-20060094769-A1 Novel aminodicarboxylic acid derivatives having pharmaceutical properties BAYER AKTIENGESELLSCHAFT (DE) 2006-05-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140142079-A1 PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASES, PREPARATION METHOD AND USE THEREOF PCNA, POLI, MKI67 TDP1 2183/4885MEN1 549/4885KMT2A 2526/4885
US-20090203906-A1 NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES DDC, AADAT, PTGIS TDP1 3153/4885MEN1 4572/4885KMT2A 3700/4885
US-20060094769-A1 Novel aminodicarboxylic acid derivatives having pharmaceutical properties DDC, AADAT, PTGIS TDP1 3153/4885MEN1 4572/4885KMT2A 3700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.